Aerovate Therapeutics (AVTE) Expected to Announce Earnings on Monday

Aerovate Therapeutics (NASDAQ:AVTE) is expected to be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Aerovate Therapeutics to post earnings of ($0.40) per share for the quarter.

Aerovate Therapeutics Stock Performance

Aerovate Therapeutics stock opened at $2.52 on Friday. Aerovate Therapeutics has a 52 week low of $1.25 and a 52 week high of $32.42. The firm has a market cap of $72.77 million, a P/E ratio of -0.84 and a beta of 1.01. The business’s fifty day moving average is $2.49 and its two-hundred day moving average is $2.41.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.